INS and type 1 diabetes mellitus: Clinical trials have confirmed that IL-1ra can increase insulin secretion by 2.5 times in patients with newly diagnosed type I diabetes [23]; however, the half-life of IL-1ra is short, only 4–6 h, and the ideal hypoglycemic effect can only be achieved by repeated daily administration at a dosage far higher than our experimental dosage [10].